You are in: eMedicine Specialties > Emergency Medicine > GENITOURINARY EpididymitisArticle Last Updated: Nov 29, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Catherine Tubridy, MD, Staff Physician, Combined Residency Program for Emergency Medicine and Internal Medicine, State University of New York Downstate/Kings County Hospital Centers Catherine Tubridy is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, and Medical Society of the State of New York Coauthor(s): Richard Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center Editors: Robert M McNamara, MD, FAAEM, Professor of Emergency Medicine, Temple University; Chief, Department of Internal Medicine, Section of Emergency Medicine, Temple University Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Richard Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Barry E Brenner, MD, PhD, FACEP, Program Director, Department of Emergency Medicine, University Hospitals, Case Medical Center Author and Editor Disclosure Synonyms and related keywords: epididymo-orchitis, intrascrotal inflammation, Escherichia coli, Chlamydia trachomatis, Neisseria gonorrhoeae, chemical epididymitis, epididymal abscess, testicular abscess, sterility, peritubular fibrosis, sexually transmitted epididymitis, urethritis, scrotal pain, scrotal edema, urinary frequency, urinary urgency, dysuria, urinary retention, urethral discharge, scrotal abscess, Prehn sign, candidal epididymitis INTRODUCTIONBackgroundThe epididymis is a coiled tubular structure located along the posterior aspect of the testis. It allows for the storage, maturation, and transport of sperm, connecting the efferent ducts of the testis to the vas deferens. Inflammation of the epididymis can be acute (<6 wk) or chronic and is most commonly caused by infection. PathophysiologyEpididymitis most often is due to the retrograde extension of organisms from the vas deferens and is rarely the result of hematogenous spread. Bacterial infection results in the infiltration of white blood cells into the epididymal connective tissue, with resultant congestion and edema. This inflammation can rapidly spread to the tubules, with the risk of abscess formation and necrosis of the epididymis. The causative organism is identified in 80% of patients and varies according to the age of the patient. In prepubertal males, the predominating sources are pathogens that cause bacturia (ie, coliform bacteria [Escherichia coli]). Workup should include a urologic evaluation for a genitourinary anomaly, which is present in as many as 50% of these patients. Epididymitis in this age group may also be secondary to a postinfectious inflammatory reaction to certain pathogens. Research has shown that boys with epididymitis had significantly elevated titers for Mycoplasma pneumoniae, enteroviruses, and adenoviruses when compared with control groups. Epididymitis can result from nonbacterial causes. Chemical epididymitis is due to the reflux of sterile urine causing an inflammatory response. Tuberculosis, brucellosis, schistosomiasis, Ureaplasma, prostate brachytherapy, and amiodarone have all been implicated in causing epididymitis. FrequencyUnited StatesEpididymitis is the most common cause of intrascrotal inflammation. Incidence is less than 1 case in 1,000 males per year. Mortality/MorbidityInfection of the epididymis can lead to the formation of an epididymal abscess. In addition, progression of the infection can lead to involvement of the testicle, causing epididymo-orchitis or a testicular abscess. Sepsis is a potential consequence of severe infection. Bilateral epididymitis may result in sterility due to occlusion of the ductules from peritubular fibrosis.
AgeEpididymitis is primarily a disease of adults, most commonly affecting males aged 19-40 years. CLINICALHistoryThe progression of epididymitis usually is gradual in nature, with symptoms often peaking within 24 hours of onset. Initially, the patient may note abdominal or flank pain because cellular inflammation typically begins in the vas deferens. As the inflammation descends to the lower segment of the epididymis, the patient notes discomfort localized to the scrotum. Younger patients or any patient with a sexually transmitted epididymitis may note symptoms related to urethritis. A recent history of endourethral instrumentation or urinary tract infection is more common in older patients. Symptoms include the following:
Physical
Causes
DIFFERENTIALSHydrocele Orchitis Testicular Torsion Urinary Tract Infection, Male
|
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin that has broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. By binding to one or more of the penicillin-binding proteins, it arrests bacterial cell wall synthesis and inhibits bacterial growth. |
| Adult Dose | 250-1000 mg IM once |
| Pediatric Dose | Infants and children: 50-75 mg/kg/d IV divided q12h; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment; caution in breastfeeding women and those allergic to penicillin |
| Drug Name | Doxycycline (Bio-Tab, Doryx, Vibramycin) |
|---|---|
| Description | Inhibits protein synthesis and bacterial growth by binding with the 30S and, possibly, the 50S ribosomal subunits of susceptible bacteria. |
| Adult Dose | 100 mg PO bid for 10-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 2-5 mg/kg/d in 1-2 divided doses; not to exceed 200 mg/d |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Azithromycin (Zithromax) |
|---|---|
| Description | Used to treat mild-to-moderate infections caused by susceptible strains of microorganisms. Indicated for chlamydial and gonorrheal infections of the genital tract. |
| Adult Dose | 1 g PO once |
| Pediatric Dose | <6 months: Not established >6 months: 10 mg/kg PO day 1; 5 mg/kg PO qd days 2-5 |
| Contraindications | Documented hypersensitivity; hepatic impairment Sudden death may occur when azithromycin is taken concurrently with pimozide |
| Interactions | May increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Site reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in hospitalized, geriatric, or debilitated patients |
| Drug Name | Trimethoprim, sulfamethoxazole (Septra DS, Bactrim DS) |
|---|---|
| Description | Inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. This results in the inhibition of bacterial growth. The antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa. |
| Adult Dose | 1 tab PO bid for 10-14 d |
| Pediatric Dose | <2 months: Do not administer >2 months: 8 mg/kg TMP and 40 mg/kg SMZ qd |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly persons; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholics, elderly persons, those receiving anticonvulsant therapy, or those with malabsorption syndrome); hemolysis may occur in G-6-PD deficient individuals; AIDS patients may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation |
| Drug Name | Ciprofloxacin (Cipro) |
|---|---|
| Description | An alternative to Septra DS; a bactericidal antibiotic that inhibits bacterial DNA synthesis, and, consequently, growth, by inhibiting DNA-gyrase in susceptible organisms. Indicated for pseudomonal infections and those that are due to multi-drug-resistant gram-negative organisms. Duration of treatment depends upon severity of infection. Generally, continue therapy for at least 2 d after the signs and symptoms of infection have disappeared. Usual treatment duration is 7-14 d. |
| Adult Dose | 500 mg PO bid for 10-14 d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Michael B Brooks, MD, to the development and writing of this article.
Article Last Updated: Nov 29, 2007